$HRTIS #Herantis Pharma Oyj Herantis Pharma - CDNF early data show biological promise: Herantis has announced top-line data from the first part of the Phase I/II clinical trial on novel asset CDNF in Parkinson’s disease (PD). Data… https://t.co/NThafwwIQd #equity #stocks https://t.co/PrIC0l3edD